LANGER DENNIS 4

What Happened

• Dennis Langer, a director of Quoin Pharmaceuticals, was granted a derivative award on February 4, 2026 covering 21,709 American Depositary Shares (ADSs). The filing reports an acquisition price of $0.00 (a grant/award), so no cash changed hands at grant.
• The 21,709 ADSs equate to 759,815 ordinary shares (1 ADS = 35 ordinary shares). The award is a derivative grant (rights to acquire equity in the future), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (timely).
• Transaction type/code: Grant/Award (derivative) — reported acquisition price $0.00.
• Securities: 21,709 ADSs granted (equivalent to 759,815 ordinary shares).
• Vesting (Footnote F2): 20% vest on each of Feb 4, 2027, 2028 and 2029; 40% vests on Feb 4, 2030.
• Footnote (F1): Numbers are expressed in ADSs; each ADS represents 35 ordinary shares.
• Shares owned after the reported transaction: not disclosed in the provided filing.

Context

• This is a compensation-style derivative award (common for directors) that vests over time; it does not represent an immediate market purchase or sale and therefore is not a short-term bullish signal like an immediate open-market buy.
• For retail investors, note derivative awards align executive incentives over the vesting period but do not by themselves indicate immediate insider conviction to buy or sell shares.